Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome

Leukemia

Volumn 13, Issue 10, 1999, Pages 1574-1580

  Salomons, G S ^a   Smets, L A ^a   Verwijs Janssen, M ^a   Hart, A A M ^a   Haarman, E G ^b   Kaspers, G J L ^b   Van Wering, E R ^c   Van Der Does Van Den Berg, A ^c   Kamps, W A ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Dutch Childhood Leukemia Study Group   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Apoptosis; Bcl 2 family; Drug resistance

Indexed keywords

ASPARAGINASE; METHOTREXATE; METHYL GROUP; PREDNISOLONE; PROTEIN BAX; PROTEIN BCL 2; TETRAZOLIUM; THIAZOLE DERIVATIVE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASSAY; B CELL LEUKEMIA; CELL CYCLE S PHASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN CELL; INFANT; INTRATHECAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA;

EID: 0032847005     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401529     Document Type: Article

References (36)

1. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
2. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-7443.
3. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386-401.
4. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-473.
5. Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ. Baxα perturbs T cell development and affects cell cycle entry of T cells. EMBO J 1996; 15: 6991-7001.
6. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 1996; 93: 9545-9552.
7. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996; 271: 12695-12698.
8. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226.
9. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979-6990.
10. Winter JN, Andersen J, Reed JC, Krajewski S, Variakojis D, Bauer KD, Fisher RI, Gordon LI, Oken MM, Jiang S, Jeffries D, Domer P. BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 1998; 91: 1391-1398.
11. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
12. Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, EK O, Zeren T, Tubergen D, Reaman G, Gaynon P. Cellular expression of anti-apoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood 1997; 89: 3769-3777.
13. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-1146.
14. Salomons GS, Brady HJ, Verwijs-Janssen M, Van Den Berg JD, Hart AA, Van Den Berg H, Behrendt H, Hählen K, Smets LA. The Baxα:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 1997; 71: 959-965.
15. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.
16. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993; 4: 327-332.
17. Kamps WA, Bökkerink JPM, Hählen K, Hermans J, Riehm H, Gadner H, Schrappe M, Slater R, Smets LA, de Vaan GAM, Weening RS, van Weerden JF, Van Wering ER, Van Der Does-Van Den Berg A. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: results of DCLSG protocol ALL-7. Blood 1999; 94 (in press).
18. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
19. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
20. Smets LA, Slater R, Van Wering ER, Van Der Does-Van Den Berg A, Hart AA, Veerman AJ, Kamps WA. DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: a report from studies ALL V, ALL VI, and ALL VII (1979-1991) of the Dutch Childhood Leukemia Study Group and The Netherlands Workgroup on Cancer Genetics and Cytogenetics. Med Ped Oncol 1995; 25: 437-444.
21. Slater RM, Smeets DF, Hagemeijer A, De Jong B, Beverstock CG, Geraedts JP, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJ. Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group. Haematol Blood Transf 1990; 33: 169-173.
22. Cox DR. Regression models and life-tables. JR Stat Soc 1972; 34: 187-220.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-481.
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard V, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
25. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266.
26. Smets LA, van den Berg J, Acton D, Top B, Van Rooij H, Verwijs-Janssen M. BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994; 84: 1613-1619.
27. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994; 54: 3714-3717.
28. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Masson DY. bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med 1993; 329: 690-694.
29. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 concoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237-241.
30. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997; 89: 2986-2993.
31. Brady HJ, Salomons GS, Bobeldijk RC, Berns AJ. T cells from Baxα transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 1996; 15: 1221-1230.
32. Smets LA, Salomons G, Van Rooij H, van den Berg J. Involvement of the glucocorticoid receptor in stress-induced apoptosis of leukemic cells. Leukemia 1998; 12: 406-413.
33. Smets LA, Van Den Berg JD. Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leuk Lymphoma 1996; 20: 199-205.
34. Strasser-Wozak EM, Hattmannstorfer R, Hala M, Hartmann BL, Fiegl M, Celey S, Kofler R. Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell line. Cancer Res 1995; 55: 348-353.
35. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000.
36. Rubnitz JE, Pui CH. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol 1997; 4: 233-241.